Canopy Growth Rally Faces Headwinds Despite U.S. Marijuana Rescheduling

Canopy Growth (NASDAQ: CGC) has seen a significant short-term price recovery, rallying over 30% in the past month. This momentum follows the U.S. government's announcement to reschedule medical marijuana from Schedule I to Schedule III, a move that has reignited investor optimism across the cannabis sector. While the rescheduling is a positive signal for the broader industry, the actual benefits are primarily skewed toward U.S.-based multi-state operators. These companies stand to benefit from significantly lower tax bills, whereas Canopy Growth remains limited by its Canadian operations and lack of a direct U.S. presence. Until full federal legalization occurs, the company remains effectively in the same operational position it held prior to the announcement. The company's long-term trajectory remains precarious. From a peak market capitalization of approximately $11 billion five years ago, Canopy Growth has seen its valuation plummet by 95% to roughly $500 million. This decline reflects years of poor results and failed expectations regarding U.S. reform. Despite shifting to an 'asset-light' model to curb spending, the company continues to struggle with profitability. Canopy Growth reported losses totaling 327 million Canadian dollars over the trailing 12 months, suggesting that the business has not yet stabilized. Investors are cautioned that the current rally may be short-lived. Without a clear path to enter the U.S. market, the stock's recent gains appear to be driven more by industry-wide sentiment than by a fundamental improvement in Canopy Growth's own financial health.